1 BTC
=
- USD
TScan Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About TScan Therapeutics, Inc. Common Stock
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Market Statistics
Trading Metrics
How to Buy TCRX
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy TCRX
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesTScan Therapeutics reported Q1 2026 financial results with net loss of $28.7 million and revenue of $1.0 million. The company announced multiple clinical milestones including early data from Cohort C of its Phase 1 ALLOHA trial expected in Q2 2026, planned Phase 3 initiation of TSC-101 in Q2 2026, and Phase 1 studies of TSC-102-A01 and TSC-102-A03 in H2 2026. Cash position of $128.1 million is expected to fund operations into H2 2027.
TScan Therapeutics, a clinical-stage biotech company developing TCR-engineered T cell therapies for cancer treatment, announced participation in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company reported completion of enrollment in Cohort C of its Phase 1 ALLOHAâ„¢ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for candidates TSC-102-A01 and TSC-102-A03.
TScan Therapeutics completed enrollment in Cohort C of its Phase 1 ALLOHAâ„¢ trial using a commercial-ready manufacturing process and received FDA clearance for investigational new drug applications for TSC-102-A01 and TSC-102-A03 candidates targeting CD45 for patients with HLA types A*01:01 and A*03:01. The company plans to share safety and chimerism data in Q2 2026 and launch a pivotal trial for TSC-101, while initiating Phase 1 studies for both TSC-102 candidates in the second half of 2026.
TScan Therapeutics reported promising results from its Phase 1 trial of TSC-101 for hematologic malignancies, showing improved relapse-free survival and no dose-limiting toxicities in patients undergoing bone marrow transplantation.
